Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
Status:
Completed
Trial end date:
2018-05-15
Target enrollment:
Participant gender:
Summary
The primary objective of step 1 is the rate of adverse events of minocycline and bevacizumab
during reirradiation and of step 2 is the response rate to bevacizumab, reirradiation, and
minocycline. The secondary objectives are the response rate, Progression Free Survival
(PFS)-3, PFS-6, and effects on quality of life and cognition from repeat radiation and
bevacizumab.